Months into the COVID-19 pandemic, Dr. Charity Dean realized a harsh reality. She was then assistant director of the California Department of Public Health, and she knew the state and nation were literally in a do-or-die situation. “As a local health officer, I learned painfully that no one is coming to save me,” Dean, who Read More →
Oxnard-based Cure Pharmaceutical saw another spike in revenue in the first quarter of 2021, but net losses also continued to grow. Cure had $1.5 million in revenue in the quarter ended March 31, up 400% from the first quarter of 2020, according to the company’s earnings report, released May 17. The bulk of that growth Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Westlake Village-based biotech company MannKind saw a slight bump in revenue in the first quarter thanks to its product Afrezza, but net losses continued to climb. MannKind released its earnings after the markets closed on May 12. It ended the day down 8.6% and regained 0.25% on May 13, to close at $4.03. MannKind, which Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Westlake Village-based Arcutis Biotherapeutics suffered a net loss in the first quarter of fiscal year 2021, but continues to hold a strong financial position with $446.5 million in assets. According to earnings released May 4, Arcutis lost $36 million in the first quarter, or 76 cents per share, compared to a loss of $28 million, Read More →